Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of phase 1 clinical data for TNX-1500, an investigational monoclonal antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE